bioequivalence study of Gabapentine 300 mg capsule in comparison to innovator product
Not Applicable
Recruiting
- Conditions
- In the present study, no diseases will be examined and products will be administered by healthy volunteers..
- Registration Number
- IRCT20210519051345N3
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart and Kidney),
Age (20-60)
Exclusion Criteria
Smoking,
history of cardiovascular disease,
history of liver and kidney disease,
pregnancy,
alcohol and drug addiction,
history of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma Drug Concentration. Timepoint: 0.5-24 hours in predetermined time intervals after drug administration. Method of measurement: Using high performance liquid chromatography (HPLC).
- Secondary Outcome Measures
Name Time Method